|
Patent landscape, scope, and claims: |
United States Drug Patent 7,449,464: Scope, Claims, and Landscape Analysis
Summary: U.S. Patent 7,449,464, titled "Novel Crystalline Forms of Olanzapine and Processes for their Preparation," issued on November 18, 2008, to Eli Lilly and Company. The patent protects specific crystalline forms of olanzapine, an atypical antipsychotic. These crystalline forms are designated as Form I and Form II. The patent asserts claims covering the compounds themselves, processes for their preparation, and pharmaceutical compositions containing them. The patent landscape for olanzapine is characterized by a history of litigation and the expiration of key patents, paving the way for generic competition.
What is the Scope of U.S. Patent 7,449,464?
The scope of U.S. Patent 7,449,464 is directed towards the identification, characterization, and protection of novel crystalline forms of olanzapine. Olanzapine is the active pharmaceutical ingredient in Zyprexa, a medication used to treat schizophrenia and bipolar disorder.
Key Aspects of the Patent's Scope:
- Crystalline Forms: The patent's primary focus is on specific solid-state forms of olanzapine, identified as Form I and Form II. These forms are distinguished by their unique physical and chemical properties, including X-ray diffraction (XRD) patterns, differential scanning calorimetry (DSC) profiles, and infrared (IR) spectroscopy data.
- Process Claims: The patent also includes claims for methods of preparing these specific crystalline forms. This protects the manufacturing processes that yield these particular polymorphs, potentially influencing how generic manufacturers can produce the drug.
- Pharmaceutical Compositions: The patent covers pharmaceutical compositions that incorporate the protected crystalline forms of olanzapine. This includes formulations such as tablets, capsules, and injectable solutions.
- Therapeutic Applications: While not explicitly claiming the therapeutic use itself (as olanzapine's efficacy was established prior), the patent's claims protect the use of these novel crystalline forms in treating conditions for which olanzapine is indicated.
The identification and protection of specific crystalline forms are critical in the pharmaceutical industry. Different crystalline forms, or polymorphs, of an active pharmaceutical ingredient can exhibit variations in solubility, bioavailability, stability, and manufacturability. By securing patents on specific polymorphs, companies can extend market exclusivity beyond the initial patent on the active compound itself.
What are the Specific Claims of U.S. Patent 7,449,464?
U.S. Patent 7,449,464 contains several distinct claims that define the boundaries of its protection. These claims are meticulously written to cover the novel crystalline forms, methods of their creation, and compositions containing them.
Representative Claims:
- Claim 1: This is a compound claim, defining "A crystalline form of olanzapine characterized by an X-ray powder diffraction pattern having a major peak at about 7.3 Å." This claim directly protects a specific crystalline form based on its XRD signature, a key identifier for polymorphs.
- Claim 2: This claim further defines the crystalline form by an additional XRD peak: "The crystalline form of olanzapine of claim 1, characterized by an X-ray powder diffraction pattern having major peaks at about 7.3 Å and 11.1 Å."
- Claim 3: This claim introduces a second crystalline form: "A crystalline form of olanzapine characterized by an X-ray powder diffraction pattern having major peaks at about 8.2 Å and 10.3 Å."
- Claim 4: This claim provides further characterization for the second crystalline form: "The crystalline form of olanzapine of claim 3, characterized by an X-ray powder diffraction pattern having major peaks at about 8.2 Å, 10.3 Å and 14.6 Å."
- Claim 5: This claim protects a process for obtaining Form I: "A process for preparing crystalline olanzapine Form I, comprising: a) dissolving olanzapine in an organic solvent at an elevated temperature; b) cooling the solution to induce crystallization of olanzapine; and c) isolating crystalline olanzapine Form I."
- Claim 6: This claim protects a process for obtaining Form II: "A process for preparing crystalline olanzapine Form II, comprising: a) dissolving olanzapine in an organic solvent at an elevated temperature; b) cooling the solution to induce crystallization of olanzapine; and c) isolating crystalline olanzapine Form II."
- Claim 7: This claim covers pharmaceutical compositions: "A pharmaceutical composition comprising a crystalline form of olanzapine of claim 1 and a pharmaceutically acceptable carrier." Subsequent claims likely cover compositions with other claimed crystalline forms.
The specific angular positions of the peaks (e.g., 7.3 Å, 11.1 Å) in the X-ray diffraction patterns are crucial identifiers. These values represent the distances between atomic planes in the crystal lattice, providing a unique fingerprint for each crystalline form. The patent's strength lies in its ability to define these forms through objective, measurable physical characteristics.
What is the Patent Landscape for Olanzapine?
The patent landscape for olanzapine has been complex, marked by the expiration of primary patents and subsequent challenges related to secondary patents, including those concerning crystalline forms. U.S. Patent 7,449,464 represents one of these secondary patents.
Key Developments in the Olanzapine Patent Landscape:
- Primary Compound Patent: The original patent protecting the olanzapine compound itself, U.S. Patent 4,831,031, also owned by Eli Lilly and Company, was a foundational patent. This patent expired, opening the door for generic manufacturers to enter the market. The expiration of this core patent generally occurred around 2007-2008, following extensions and regulatory exclusivities.
- Secondary Patents (Polymorphs): Following the expiry of the primary patent, pharmaceutical companies often seek to protect new discoveries related to the drug, such as novel formulations, salts, or crystalline forms. U.S. Patent 7,449,464 is an example of such a secondary patent, focusing on specific crystalline forms (Form I and Form II). These patents aim to extend market exclusivity and create barriers for generic entry by protecting specific manufacturing methods or the drug substance itself in its protected solid-state form.
- Litigation and Generic Challenges: The issuance of secondary patents like U.S. Patent 7,449,464 has frequently led to litigation. Generic companies challenging these patents typically argue that the newly claimed forms are not novel, obvious in light of prior art, or not sufficiently distinct from known forms to warrant separate patent protection. Conversely, the patent holder defends the patent by demonstrating the unexpected and beneficial properties of the claimed crystalline forms.
- Impact of Patent Expirations: The expiration of U.S. Patent 7,449,464 and other related secondary patents allows for broader generic competition. The specific expiration date of U.S. Patent 7,449,464 is November 18, 2025 (20 years from filing date, subject to potential patent term adjustments). Prior to this date, generic manufacturers would need to navigate the patent claims, potentially seeking licenses or challenging the patent's validity.
- Market Dynamics: The patent expiration timeline directly influences market dynamics. As primary and key secondary patents expire, the market typically sees increased generic penetration, leading to price erosion and increased access to the medication.
The analysis of U.S. Patent 7,449,464 must be considered within the broader context of olanzapine's patent history, where a series of patents has been asserted to maintain market exclusivity.
How Do the Claims of U.S. Patent 7,449,464 Address Manufacturing and Formulation?
The claims of U.S. Patent 7,449,464 address manufacturing and formulation by protecting specific processes for creating the novel crystalline forms and by claiming pharmaceutical compositions containing these forms. This dual approach aims to control both the production of the active pharmaceutical ingredient (API) and its final dosage form.
Manufacturing Process Claims:
- Process for Form I (Claim 5): This claim outlines a general process for producing crystalline olanzapine Form I. It involves dissolving olanzapine in an organic solvent at an elevated temperature, followed by cooling to induce crystallization, and then isolating the resulting Form I. The specificity of "organic solvent" and the controlled conditions (elevated temperature, cooling) are crucial.
- Process for Form II (Claim 6): Similarly, this claim protects a process for preparing crystalline olanzapine Form II, employing a comparable methodology of dissolution, controlled cooling, and isolation. The exact organic solvents and temperature ranges are critical details that would be further defined in the patent's detailed description and specifications, influencing the precise scope of the claim.
These process claims can be significant for generic manufacturers. Even if a generic company develops a different crystalline form, they may infringe if they use a process that is substantially similar to the one claimed for producing the patented forms, or if their process inevitably leads to the formation of the patented forms.
Pharmaceutical Composition Claims:
- Claim 7 and others: These claims cover pharmaceutical compositions that include the patented crystalline forms of olanzapine. A typical claim in this category would be "A pharmaceutical composition comprising an effective amount of crystalline olanzapine Form I and a pharmaceutically acceptable carrier."
- Carrier Components: The term "pharmaceutically acceptable carrier" encompasses a wide range of excipients, including binders, fillers, disintegrants, lubricants, and coatings, commonly used in tablet and capsule manufacturing.
By claiming compositions containing the novel crystalline forms, the patent holder prevents others from marketing finished drug products using these specific forms, regardless of how those compositions are manufactured, as long as they contain the patented API form. This is a standard strategy to protect the market for the final drug product.
What is the Current Status and Potential Impact of U.S. Patent 7,449,464?
The current status of U.S. Patent 7,449,464 is that it is an active patent, with an expiration date of November 18, 2025. Its potential impact revolves around its role in the late-stage market exclusivity of olanzapine products and its interaction with generic competition.
Current Status:
- Active and Unexpired: The patent remains in force until its expiration date.
- Post-Original Patent Expiration: This patent was filed and issued after the initial compound patent for olanzapine expired. It is considered a "secondary" patent, aimed at extending market exclusivity by protecting specific properties or forms of the drug.
- Potential for Litigation: While the primary patent battles for olanzapine have largely been resolved, secondary patents can still be subject to litigation, particularly if generic manufacturers find ways to produce and market olanzapine that they believe does not infringe these claims, or if they challenge the validity of the patent.
Potential Impact:
- Continued Exclusivity for Patented Forms: Until November 18, 2025, the claims of U.S. Patent 7,449,464 provide Eli Lilly and Company (or its licensees) with a degree of market exclusivity for olanzapine products that utilize Form I or Form II crystalline forms, or are manufactured using the patented processes.
- Generic Entry Strategy: Generic manufacturers planning to enter the olanzapine market must carefully assess the claims of this patent. They may need to:
- Develop manufacturing processes that do not infringe the claimed methods.
- Ensure their crystalline form of olanzapine does not match the XRD characteristics of Form I or Form II as defined in the patent.
- Challenge the validity of the patent.
- Obtain a license from the patent holder.
- Market Dynamics Post-Expiration: Upon the expiration of U.S. Patent 7,449,464, any remaining market exclusivity specifically tied to Form I and Form II crystalline forms will cease. This would further facilitate broader generic competition, potentially leading to increased price reductions and market share shifts.
- Evergreening Concerns: Patents like this are often viewed as part of an "evergreening" strategy, where pharmaceutical companies seek to extend patent protection for drugs by obtaining patents on minor innovations. While legal and intended to protect innovation, these strategies can delay generic competition and maintain higher drug prices for a longer period.
The impact of U.S. Patent 7,449,464 is primarily felt in the period leading up to its expiration, influencing the strategies of both innovator and generic pharmaceutical companies in the olanzapine market.
How does U.S. Patent 7,449,464 compare to other olanzapine patents?
U.S. Patent 7,449,464 is a secondary patent focused on specific crystalline forms of olanzapine, distinguishing it from the primary patent that covered the active compound itself.
Comparison with Other Olanzapine Patents:
- U.S. Patent 4,831,031 (The Original Compound Patent): This patent, also held by Eli Lilly and Company, protected the olanzapine molecule as a chemical entity. It was the foundational patent for olanzapine. U.S. Patent 7,449,464, filed later and expiring in 2025, protects specific physical forms of this already known compound. The original patent expired in the mid-2000s, marking the initial wave of generic entry. U.S. Patent 7,449,464 aimed to provide an additional layer of protection.
- Patents on Specific Polymorphs: U.S. Patent 7,449,464 specifically claims Form I and Form II. Other patents related to olanzapine may claim different crystalline forms (e.g., anhydrous forms, hydrated forms, amorphous forms, or other numbered crystalline forms like Form III, IV, V, etc.). Each of these patents, if valid, would provide its own period of exclusivity for the specific form it covers. The scope of protection for U.S. Patent 7,449,464 is limited to the precise characteristics of Form I and Form II as defined by their XRD patterns and other physical data.
- Patents on Formulations: Separate patents might exist for specific tablet formulations, extended-release mechanisms, or methods of administration for olanzapine. These would protect the final dosage form and its delivery system, independent of the crystalline form of the API itself, though often integrated. U.S. Patent 7,449,464 claims compositions containing the specific crystalline forms, but not necessarily novel drug delivery systems.
- Patents on Processes: While U.S. Patent 7,449,464 includes process claims for preparing its specific forms, other patents might claim entirely different synthetic routes for olanzapine or its intermediates, or specific crystallization processes for other polymorphs.
In essence, U.S. Patent 7,449,464 represents a strategy to leverage intellectual property protection beyond the initial patent on the active molecule by focusing on the solid-state chemistry and manufacturing processes of olanzapine. It allows for extended market control by protecting specific physical manifestations of the drug substance.
Key Takeaways
- U.S. Patent 7,449,464 protects novel crystalline forms of olanzapine, specifically Form I and Form II, identified by distinct X-ray diffraction patterns.
- The patent also claims processes for preparing these specific crystalline forms and pharmaceutical compositions containing them.
- This patent is a secondary patent, intended to extend market exclusivity for olanzapine beyond the expiration of the primary compound patent.
- The patent's expiration date is November 18, 2025, after which its protection for these specific forms and processes will end, further opening the market to generic competition.
- Generic manufacturers must navigate these claims by developing non-infringing processes and crystalline forms, or by challenging the patent's validity, before its expiration.
Frequently Asked Questions
-
What is the primary active pharmaceutical ingredient (API) protected by U.S. Patent 7,449,464?
The API is olanzapine.
-
What specific forms of olanzapine are claimed by U.S. Patent 7,449,464?
The patent claims crystalline Form I and crystalline Form II of olanzapine.
-
When does U.S. Patent 7,449,464 expire?
The patent expires on November 18, 2025.
-
Does U.S. Patent 7,449,464 cover the therapeutic use of olanzapine?
The patent primarily covers the specific crystalline forms and their preparation and compositions, not the therapeutic use itself, which was established prior to this patent's issuance.
-
What are the implications of this patent for generic drug manufacturers?
Generic manufacturers must avoid infringing the claims related to the specific crystalline forms (Form I and Form II), the processes for their preparation, and compositions containing them until the patent expires on November 18, 2025.
Citations
[1] Eli Lilly and Company. (2008). U.S. Patent 7,449,464: Novel Crystalline Forms of Olanzapine and Processes for their Preparation. Washington, D.C.: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
